You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
After pilot programs showed patients and physicians are interested in genomics, NorthShore is working on "hardwiring" genetics into routine care.
The firm looks to win new customers among US providers while also partnering with IVD companies to embed its lab data analysis tools in their instruments.
The company trimmed its net loss fell by three-fourths to $11.8 million in the quarter as it continues to rein in costs.
Founded by former Inteliquet CEO Carla Balch, the firm is building on visualization technology to help physicians incorporate MDx testing into their practice.
The system, called Galen Prostate, uses a proprietary algorithm to help pathologists detect and grade prostate cancer in biopsies.
The companies will join their respective technologies to provide pharmacogenomic information for patients undergoing genetic testing.
BD will supply its diagnostics and informatics products as part of the contract with Fleming Fund to take on AMR in Asia and sub-Saharan Africa.
The FDA has been prodding labs performing pharmacogenetic testing, and software firms providing reports from such testing, to undergo regulatory review.
The University of Utah spinout said it will use the funding to enhance and expand its NGS-based Explify microbe identification platform and support its lab.
The findings should spur cancer centers to review testing rates and address barriers, said experts from Hackensack University, Cota Healthcare, and Guardant Health.
The partners will use Noscendo's Disqver next-generation sequencing-based diagnostic platform to characterize antibiotic-resistant pathogens.
Blueprint provides 3,900 targeted single-gene and more than 200 panel tests covering 14 medical specialties, leveraging NGS and bioinformatics methods.
An international group of researchers aim to develop an approach that may be able to diagnose multiple conditions, including pneumonia, tuberculosis, sepsis, with one blood sample.
CE marking of PromarkerD Hub complements the CE mark that the mass spectrometry version of the test received in November.
The group aims to validate the tool, called OncoWatch, in a study involving nine countries this year.
While it was developed and validated for brain tumor classification, the workflow could be extended to other cancers where intraoperative histology is valuable.
The startup company will use the money to develop its microbial tests and AI-based software for surveillance and prevention of hospital-acquired infections.
The Dutch companies will use sequencing- and machine learning-based methods to quantify genomic instability-causing mutations in blood cells.
After comparing manual methods with the firm's pcr.ai tool in more than 20,000 cases, they found that the use of AI improved test accuracy and reliability.
The platform matches a patient's medical history and other data with national guidelines to recommended medically actionable genetic tests.